Novavax, Inc. (NASDAQ: NVAX) is a biotechnology company based in Gaithersburg, Maryland, specializing in the development and commercialization of vaccines to prevent serious infectious diseases. Since its founding in 1987, Novavax has focused on a recombinant nanoparticle technology platform combined with its proprietary Matrix-M adjuvant to enhance immune responses. The company’s approach centers on producing virus-like protein nanoparticles that mimic the structure of pathogens without containing live virus, aiming to deliver strong and durable immunity with favorable safety profiles.
Novavax gained global recognition with its COVID-19 vaccine candidate, NVX-CoV2373 (marketed as Nuvaxovid in certain regions), which demonstrated robust efficacy in late-stage clinical trials. Building on the success of its COVID-19 program, the company is advancing a diversified pipeline of vaccine candidates targeting seasonal influenza, respiratory syncytial virus (RSV) in both older adults and infants, and malaria. Each candidate leverages Novavax’s nanoparticle and Matrix-M technology to address unmet medical needs by eliciting broad protection against diverse viral strains.
With research and manufacturing facilities spanning North America, Europe, Australia and partnerships in Asia, Novavax maintains a global footprint designed to support clinical development, scale manufacturing and distribution. Strategic collaborations include a partnership with the Serum Institute of India for large-scale production of its COVID-19 vaccine under the COVAX initiative, as well as alliances with governmental and non-profit organizations to ensure equitable access in emerging markets. The company’s integrated model encompasses in-house bulk drug substance production, contract manufacturing, and fill-finish capabilities.
Leadership at Novavax is headed by President and Chief Executive Officer Stanley C. Erck, who has guided the company’s transition from early research through commercialization phases since 2011. Supported by a management team with deep expertise in vaccine development, regulatory affairs and global supply chain, Novavax is committed to advancing its mission of delivering next-generation vaccines. The company continues to explore opportunities to expand its pipeline and partnerships, positioning itself as a contender in the global vaccine market.
AI Generated. May Contain Errors.
Free NVAX Stock Alerts